---
document_datetime: 2025-12-02 05:14:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tivicay.html
document_name: tivicay.html
version: success
processing_time: 0.1150587
conversion_datetime: 2025-12-26 09:52:41.51421
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tivicay

[RSS](/en/individual-human-medicine.xml/66055)

##### Authorised

This medicine is authorised for use in the European Union

dolutegravir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tivicay](#news-on)
- [More information on Tivicay](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tivicay is a medicine used together with other medicines to treat adults and children from 4 weeks of age and weighing at least 3 kg who are infected with human immunodeficiency virus (HIV), a virus that causes acquired immune deficiency syndrome (AIDS).

Tivicay contains the active substance dolutegravir.

Expand section

Collapse section

## How is Tivicay used?

Tivicay can only be obtained with a prescription and should be prescribed by a doctor who is experienced in managing HIV infection.

Tivicay is available as tablets and dispersible tablets, which have different doses and should not be interchanged without dose adjustment. The adult dose depends on whether the infection is known or suspected to be resistant to medicines of the class to which Tivicay belongs (integrase inhibitors), and whether patients are also taking certain medicines that decrease the effectiveness of Tivicay.

The dose for children depends on the age and weight of the child; children aged 6 years and above and weighing at least 14 kg are normally given tablets while dispersible tablets must be used in younger children.

Although Tivicay can normally be taken with or without food, patients whose virus is resistant to this class of medicines should take Tivicay with food, as it helps the medicine to be absorbed better.

For more information about using Tivicay, see the package leaflet or contact your doctor or pharmacist.

## How does Tivicay work?

The active substance in Tivicay, dolutegravir, is an integrase inhibitor. This is an antiviral medicine that blocks an enzyme called integrase that the virus needs to make new copies of itself in the body. Tivicay does not cure HIV infection, but when given with other medicines it reduces the amount of virus in the body and keeps it at a low level. This holds off damage to the immune system and the development of infections and diseases associated with AIDS.

## What benefits of Tivicay have been shown in studies?

Tivicay was effective against HIV-1 in four main studies. The main measure of effectiveness in all the studies was the response rate, which was the proportion of patients with an undetectable level of the virus (below 50 copies per ml).

Two studies involved patients who had not previously been treated for HIV:

- In the first of these, involving 822 patients, Tivicay once daily was compared with raltegravir (another integrase inhibitor), both given in combination with two other HIV medicines of a different class (known as nucleoside reverse transcriptase inhibitors or NRTIs): 88% of those given Tivicay and 85% of those given raltegravir responded after 48 weeks of treatment.
- The second study involved 833 patients given either a combination of Tivicay with two NRTIs or a different three-drug combination (Atripla) that did not include an integrase inhibitor. The response rate at 48 weeks was 88% in those given Tivicay-based treatment compared with 81% in those given Atripla.

Two other studies looked at the effectiveness of Tivicay in patients whose previous HIV treatment had stopped working:

- The first of these involved 724 patients whose previous treatment had not included an integrase inhibitor and whose infection was therefore not expected to be resistant to this class of medicines. Patients were treated with a combination of HIV medicines that included either Tivicay or raltegravir. Response rate at 48 weeks was 71% in patients given treatment based on Tivicay and 64% in those given treatment based on raltegravir.
- The second study involved 183 patients with infection resistant to previous treatment that had involved an integrase inhibitor (i.e., their infection was resistant to several classes of medicine, including previous integrase inhibitors). Adding Tivicay twice daily to other treatment resulted in a response rate of 69% after 24 weeks of therapy.

Studies were also carried out to show that recommended doses of tablets and dispersible tablets in children produced levels of the active substance in the body that are effective in controlling the virus.

## What are the risks associated with Tivicay?

The most common side effects with Tivicay (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea, and headache. More serious adverse effects that have been reported include an uncommon but severe hypersensitivity (allergic) reaction with rash and possible effects on the liver. For the full list of side effects of Tivicay, see the package leaflet.

Tivicay must not be used together with certain medicines such as fampridine (a multiple sclerosis medicine, also called dalfampridine), as this may increase the level of such medicines in the body, resulting in serious side effects.

For the full list of restrictions, see the package leaflet.

## Why is Tivicay authorised in the EU?

The European Medicines Agency noted that Tivicay had demonstrated effectiveness in both untreated and previously treated patients, including those with resistance to integrase inhibitors. The medicine was generally well tolerated, although the Agency noted the possible risk of infrequent but severe hypersensitivity reactions.

The European Medicines Agency therefore decided that Tivicay's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tivicay?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tivicay have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tivicay are continuously monitored. Side effects reported with Tivicay are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tivicay

Tivicay received a marketing authorisation valid throughout the EU on 16 January 2014.

Tivicay : EPAR - Medicine overview

Reference Number: EMA/617341/2020

English (EN) (148.41 KB - PDF)

**First published:** 05/02/2014

**Last updated:** 04/02/2021

[View](/en/documents/overview/tivicay-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-386)

български (BG) (171.79 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/bg/documents/overview/tivicay-epar-medicine-overview_bg.pdf)

español (ES) (148.12 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/es/documents/overview/tivicay-epar-medicine-overview_es.pdf)

čeština (CS) (170.75 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/cs/documents/overview/tivicay-epar-medicine-overview_cs.pdf)

dansk (DA) (146.39 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/da/documents/overview/tivicay-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.74 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/de/documents/overview/tivicay-epar-medicine-overview_de.pdf)

eesti keel (ET) (133.78 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/et/documents/overview/tivicay-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.89 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/el/documents/overview/tivicay-epar-medicine-overview_el.pdf)

français (FR) (147.76 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/fr/documents/overview/tivicay-epar-medicine-overview_fr.pdf)

hrvatski (HR) (168.37 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/hr/documents/overview/tivicay-epar-medicine-overview_hr.pdf)

italiano (IT) (145.46 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/it/documents/overview/tivicay-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (166.08 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/lv/documents/overview/tivicay-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (167.38 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/lt/documents/overview/tivicay-epar-medicine-overview_lt.pdf)

magyar (HU) (168.64 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/hu/documents/overview/tivicay-epar-medicine-overview_hu.pdf)

Malti (MT) (170.8 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/mt/documents/overview/tivicay-epar-medicine-overview_mt.pdf)

Nederlands (NL) (147 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/nl/documents/overview/tivicay-epar-medicine-overview_nl.pdf)

polski (PL) (174.08 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/pl/documents/overview/tivicay-epar-medicine-overview_pl.pdf)

português (PT) (148.24 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/pt/documents/overview/tivicay-epar-medicine-overview_pt.pdf)

română (RO) (166.84 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/ro/documents/overview/tivicay-epar-medicine-overview_ro.pdf)

slovenčina (SK) (169.6 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/sk/documents/overview/tivicay-epar-medicine-overview_sk.pdf)

slovenščina (SL) (167.97 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/sl/documents/overview/tivicay-epar-medicine-overview_sl.pdf)

Suomi (FI) (143.37 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/fi/documents/overview/tivicay-epar-medicine-overview_fi.pdf)

svenska (SV) (144.14 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/sv/documents/overview/tivicay-epar-medicine-overview_sv.pdf)

Tivicay : EPAR - Risk management plan

English (EN) (810.97 KB - PDF)

**First published:** 10/12/2024

**Last updated:** 14/11/2025

[View](/en/documents/rmp/tivicay-epar-risk-management-plan_en.pdf)

## Product information

Tivicay : EPAR - Product Information

English (EN) (1.38 MB - PDF)

**First published:** 05/02/2014

**Last updated:** 14/11/2025

[View](/en/documents/product-information/tivicay-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-446)

български (BG) (2.05 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/bg/documents/product-information/tivicay-epar-product-information_bg.pdf)

español (ES) (1.8 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/es/documents/product-information/tivicay-epar-product-information_es.pdf)

čeština (CS) (2.11 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/cs/documents/product-information/tivicay-epar-product-information_cs.pdf)

dansk (DA) (1.83 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/da/documents/product-information/tivicay-epar-product-information_da.pdf)

Deutsch (DE) (2.12 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/de/documents/product-information/tivicay-epar-product-information_de.pdf)

eesti keel (ET) (1.74 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/et/documents/product-information/tivicay-epar-product-information_et.pdf)

ελληνικά (EL) (2.01 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/el/documents/product-information/tivicay-epar-product-information_el.pdf)

français (FR) (1.78 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/fr/documents/product-information/tivicay-epar-product-information_fr.pdf)

hrvatski (HR) (2.04 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/hr/documents/product-information/tivicay-epar-product-information_hr.pdf)

íslenska (IS) (1.85 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/is/documents/product-information/tivicay-epar-product-information_is.pdf)

italiano (IT) (1.98 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/it/documents/product-information/tivicay-epar-product-information_it.pdf)

latviešu valoda (LV) (1.81 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/lv/documents/product-information/tivicay-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.01 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/lt/documents/product-information/tivicay-epar-product-information_lt.pdf)

magyar (HU) (1.99 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/hu/documents/product-information/tivicay-epar-product-information_hu.pdf)

Malti (MT) (2.16 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/mt/documents/product-information/tivicay-epar-product-information_mt.pdf)

Nederlands (NL) (1.92 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/nl/documents/product-information/tivicay-epar-product-information_nl.pdf)

norsk (NO) (1.93 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/no/documents/product-information/tivicay-epar-product-information_no.pdf)

polski (PL) (1.97 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/pl/documents/product-information/tivicay-epar-product-information_pl.pdf)

português (PT) (1.88 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/pt/documents/product-information/tivicay-epar-product-information_pt.pdf)

română (RO) (2.04 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/ro/documents/product-information/tivicay-epar-product-information_ro.pdf)

slovenčina (SK) (2.18 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/sk/documents/product-information/tivicay-epar-product-information_sk.pdf)

slovenščina (SL) (1.77 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/sl/documents/product-information/tivicay-epar-product-information_sl.pdf)

Suomi (FI) (1.99 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/fi/documents/product-information/tivicay-epar-product-information_fi.pdf)

svenska (SV) (1.99 MB - PDF)

**First published:**

05/02/2014

**Last updated:**

14/11/2025

[View](/sv/documents/product-information/tivicay-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000249653 16/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tivicay : EPAR - All Authorised presentations

English (EN) (67.37 KB - PDF)

**First published:** 05/02/2014

**Last updated:** 04/02/2021

[View](/en/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-899)

български (BG) (42.09 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/bg/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_bg.pdf)

español (ES) (68.67 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/es/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.84 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/cs/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (67.69 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/da/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.5 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/de/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (68.17 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/et/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.68 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/el/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_el.pdf)

français (FR) (69.78 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/fr/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.02 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/hr/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.48 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/is/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.78 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/it/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (84.91 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/lv/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (83.6 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/lt/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.25 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/hu/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (79.47 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/mt/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.53 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/nl/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (67.99 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/no/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_no.pdf)

polski (PL) (36.75 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/pl/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_pl.pdf)

português (PT) (67.54 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/pt/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_pt.pdf)

română (RO) (42.23 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/ro/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.3 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/sk/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.64 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/sl/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.74 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/fi/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.95 KB - PDF)

**First published:**

05/02/2014

**Last updated:**

04/02/2021

[View](/sv/documents/all-authorised-presentations/tivicay-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tivicay Active substance dolutegravir International non-proprietary name (INN) or common name dolutegravir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AX12

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

## Authorisation details

EMA product number EMEA/H/C/002753 Marketing authorisation holder

ViiV Healthcare BV

Van Asch van Wijckstraat 55H

Opinion adopted 21/11/2013 Marketing authorisation issued 16/01/2014 Revision 37

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tivicay : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.29 KB - PDF)

**First published:** 14/11/2025

[View](/en/documents/procedural-steps-after/tivicay-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tivicay : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (398.88 KB - PDF)

**First published:** 29/08/2014

**Last updated:** 14/11/2025

[View](/en/documents/procedural-steps-after/tivicay-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tivicay-PAM-0000279558 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2216398

English (EN) (643.12 KB - PDF)

**First published:** 10/09/2025

[View](/en/documents/variation-report/tivicay-pam-0000279558-epar-assessment-report_en.pdf)

Tivicay : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/CHMP/106165/2023

English (EN) (110.87 KB - PDF)

**First published:** 07/03/2023

[View](/en/documents/pip-compliance/tivicay-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Tivicay-H-C-002753-P46-014 : EPAR - Assessment report

Adopted

Reference Number: EMA/260697/2021

English (EN) (243.24 KB - PDF)

**First published:** 30/06/2021

[View](/en/documents/variation-report/tivicay-h-c-002753-p46-014-epar-assessment-report_en.pdf)

Tivicay-H-C-2753-X-0058-G: EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/540603/2020

English (EN) (5.82 MB - PDF)

**First published:** 04/02/2021

[View](/en/documents/variation-report/tivicay-h-c-2753-x-0058-g-epar-assessment-report-variation_en.pdf)

Tivicay-H-C-PSUSA-00010075-202001 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/470525/2020

English (EN) (96.54 KB - PDF)

**First published:** 27/11/2020

[View](/en/documents/scientific-conclusion/tivicay-h-c-psusa-00010075-202001-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tivicay (X-58-G)

Adopted

Reference Number: EMA/CHMP/540606/2020

English (EN) (96.18 KB - PDF)

**First published:** 13/11/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tivicay-x-58-g_en.pdf)

Tivicay-H-C-002753-X-0018-G : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/601663/20177

English (EN) (1.78 MB - PDF)

**First published:** 31/10/2017

**Last updated:** 31/10/2017

[View](/en/documents/variation-report/tivicay-h-c-002753-x-0018-g-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Tivicay

Adopted

Reference Number: EMA/CHMP/816690/2016

English (EN) (67.51 KB - PDF)

**First published:** 16/12/2016

**Last updated:** 16/12/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tivicay_en.pdf)

## Initial marketing authorisation documents

Tivicay : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/772068/2013

English (EN) (1.01 MB - PDF)

**First published:** 05/02/2014

**Last updated:** 05/02/2014

[View](/en/documents/assessment-report/tivicay-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tivicay

Adopted

Reference Number: EMA/CHMP/636968/2013

English (EN) (63.01 KB - PDF)

**First published:** 22/11/2013

**Last updated:** 22/11/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tivicay_en.pdf)

#### News on Tivicay

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020) 13/11/2020

[New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir](/en/news/new-study-suggests-risk-birth-defects-babies-born-women-hiv-medicine-dolutegravir) 18/05/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2016) 16/12/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-november-2013) 22/11/2013

[European Medicines Agency recommends approval of new HIV medicine](/en/news/european-medicines-agency-recommends-approval-new-hiv-medicine) 22/11/2013

#### More information on Tivicay

- [EMEA-000409-PIP01-08-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000409-pip01-08-m06)
- [Prenatal Exposure to Dolutegravir and Pregnancy and Neonatal Outcomes: Data from Antiretroviral Pregnancy Registry (206242) - post-authorisation study](https://catalogues.ema.europa.eu/study/47350)
- [A multi-site observational study to assess safety and effectiveness of prenatal exposure to Dolutegravir in pregnant individuals living with HIV (212976) - post-authorisation study](https://catalogues.ema.europa.eu/study/42405)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/11/2025

## Share this page

[Back to top](#main-content)